{"product_id":"il-36-alpha-antibody-il-1f6-bha17106272","title":"IL-36 alpha Antibody \/ IL-1F6","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eIL-36 alpha Antibody \/ IL-1F6 is a research-use-only Rabbit polyclonal (rabbit origin) Rabbit IgG directed against \u003cstrong\u003eIL-36 alpha \/ IL-1F6\u003c\/strong\u003e. It is supplied for interpretation-focused detection and comparative profiling in WB, Direct ELISA. \u003c\/p\u003e\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTarget context:\u003c\/strong\u003e This antibody is raised against \u003cem\u003eA recombinant human protein corresponding to amino acids K6-F158 was used as the immunogen for the IL-36 alpha antibody.\u003c\/em\u003e. Epitope context matters because isoforms, processing, and post-translational modifications can change what is accessible in a given assay.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified. Format influences background and compatibility with different detection chemistries; conjugated formats (when present) can simplify multiplexing and reduce reliance on secondary reagents.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human, Mouse, Rat. Cross-species performance can vary with sequence divergence and epitope conservation, so interpretation should be anchored with appropriate biological controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eApplications:\u003c\/strong\u003e WB, Direct ELISA. These indicate assay contexts where the antibody is commonly applied; actual performance depends on sample type and processing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLimitations:\u003c\/strong\u003e This IL-36 alpha antibody is available for research use only.. Consider these constraints when selecting controls and when comparing results across sample matrices.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003ePolyclonal reagents can differ in how they recognize epitope features. Monoclonal antibodies often provide more consistent epitope targeting across lots, while polyclonal preparations may broaden recognition across related epitope variants. \u003c\/p\u003e\n\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eIL-36 alpha \/ IL-1F6\u003c\/strong\u003e refers to the gene\/protein target stated in the product record. Protein targets can exhibit context-dependent expression, regulated turnover, isoform diversity, and post-translational modifications that affect apparent molecular weight and epitope accessibility. For curated functional annotation, sequence features, and expression context, consult \u003ca href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q9UHA7\/entry\"\u003eUniProtKB Q9UHA7\u003c\/a\u003e, \u003ca href=\"https:\/\/www.ensembl.org\/\"\u003eEnsembl\u003c\/a\u003e, and \u003ca href=\"https:\/\/www.proteinatlas.org\/\"\u003eHuman Protein Atlas\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eIntegrating antibody-based detection with single-cell and spatial atlasing efforts to connect RNA programs with protein-level abundance and localization in defined cell states.\u003c\/li\u003e\n\u003cli\u003eExpanding multiplexed imaging and high-content screening, where reagent specificity, cross-reactivity risk, and channel design (including direct conjugates) become central to interpretation.\u003c\/li\u003e\n\u003cli\u003eGrowing emphasis on reproducibility and application-specific validation frameworks (e.g., genetic perturbation controls, orthogonal measurements, and independent antibody strategies) when drawing mechanistic conclusions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eWestern blot (WB):\u003c\/strong\u003e commonly used to compare relative abundance\/size (e.g., band intensity or mobility shifts) between conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDirect ELISA:\u003c\/strong\u003e commonly used for qualitative\/quantitative detection where compatible with the assay context.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpretation typically focuses on relative differences (presence\/absence, fold-changes, compartment shifts, or population-level shifts) rather than absolute quantitation. When signal changes are observed, they may reflect altered expression, altered localization\/trafficking, changes in modification state, or differences in sample composition; orthogonal readouts and appropriate controls help distinguish these possibilities.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eApplication details (record-specific):\u003c\/strong\u003e Western Blot: 0.5-1ug\/ml,Direct ELISA (recombinant human protein): 0.1-0.5ug\/ml (BSA-free format available)\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eApplication notes (record-specific):\u003c\/strong\u003e Optimal dilution of the IL-36 alpha antibody should be determined by the researcher.\u003c\/p\u003e\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct description (record-specific):\u003c\/strong\u003e Interleukin-36 alpha also known as interleukin-1 family member 6 (IL1F6) is a protein that in humans is encoded by the IL36A gene. The protein encoded by this gene is a cytokine that can activate NF-kappa-B and MAPK signaling pathways to generate an inflammatory response. The encoded protein functions primarily in skin and demonstrates increased expression in psoriasis. In addition, decreased expression of this gene has been linked to a poor prognosis in both hepatocellular carcinoma and colorectal cancer patients.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePotential confounders:\u003c\/strong\u003e isoforms, proteolytic processing, and PTMs can change epitope presentation and apparent size; fixation\/denaturation state can also expose or mask epitopes. Species differences near the epitope may affect cross-reactivity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e include genetic perturbation (KO\/KD) or overexpression comparisons, orthogonal measurement (e.g., transcript or proteomics), and independent antibody\/epitope strategies. For conjugated reagents, include staining-only\/background controls appropriate to the detection chemistry.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eImmunogen\/epitope context is described as: \u003cem\u003eA recombinant human protein corresponding to amino acids K6-F158 was used as the immunogen for the IL-36 alpha antibody.\u003c\/em\u003e. Monoclonal and polyclonal formats differ in epitope breadth; this can influence sensitivity to sequence variants, isoforms, or PTM-dependent recognition.\u003c\/p\u003e\n\u003c!-- Sources (internal):\n- UniProtKB entry Q9UHA7 (UniProt Consortium): https:\/\/www.uniprot.org\/uniprotkb\/Q9UHA7\/entry\n- Ensembl genome browser (EMBL-EBI \/ Wellcome Sanger): https:\/\/www.ensembl.org\/\n- The Human Protein Atlas (KTH \/ SciLifeLab): https:\/\/www.proteinatlas.org\/\n- A proposal for validation of antibodies (Uhlén et al., Nature Methods, 2016): https:\/\/www.nature.com\/articles\/nmeth.3995.pdf\n- Getting to reproducible antibodies: the rationale for sequenced recombinant characterized reagents (Bradbury \u0026 Plückthun, PEDS, 2015): https:\/\/academic.oup.com\/peds\/article\/28\/10\/303\/1478378\n- Standardize antibodies used in research (Bradbury, Plückthun et al., Nature, 2015): https:\/\/www.nature.com\/articles\/518027a.pdf\n--\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53210379190637,"sku":"R32986","price":462.47,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_c072e60f-b9e3-4f48-9036-9cd539f0e4b1.jpg?v=1775785836","url":"https:\/\/www.ebiohippo.com\/products\/il-36-alpha-antibody-il-1f6-bha17106272","provider":"BioHippo","version":"1.0","type":"link"}